RxDoctor Payments Data

Gloria Fabela

Family · Pharr, TXNPI 1285921056

Payments from drug & device makers

$551in general payments, 2019–2025

Across 33 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$144
  • Astellas Pharma US Inc$92
  • AbbVie$73
  • Novo Nordisk$55
  • Novartis$39
  • Johnson & Johnson$30
  • plus $117 from 7 others

What the payments were for

  • Food & beverage$45983%
  • Education$9217%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$551 in reported general payments places this provider in the 55th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$35,427
Medicare patients
172
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$148,574
MounjaroTirzepatide111$146,733
JardianceEmpagliflozin98$108,894
MyrbetriqMirabegron40$31,974
Tresiba Flextouch U-200Insulin Degludec23$26,880
RybelsusSemaglutide13$22,195
LinzessLinaclotide27$21,650
FarxigaDapagliflozin Propanediol26$18,593
TrulicityDulaglutide14$16,903
Tresiba Flextouch U-100Insulin Degludec19$16,143
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,630
Diclofenac Sodium112$3,631
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide80$1,886
Memantine Hcl52$1,371
PaxlovidNirmatrelvir/Ritonavir17$1,359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$55$170,769149 claims
Lilly USA, LLCMounjaro, Trulicity$144$163,636125 claims
Boehringer IngelheimJardiance$14$108,89498 claims
Astellas Pharma US IncMyrbetriq$92$31,97440 claims
AbbVieLinzess$73$21,65027 claims
AstraZenecaFarxiga$13$18,59326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 15,456 family providers in Texas.

Other family in Pharr

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →